Q-Line Biotech NSE SME IPO review

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies.

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended	Revenue	Expense	PAT	Assets
2023	₹184.81	₹154.97	₹32.10	₹251.58
2024	₹206.45	₹175.85	₹34.44	₹339.25
2025	₹322.58	₹261.43	₹28.13	₹455.49
Dec 2025	₹236.50	₹186.96	₹38.69	₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company	Face Value (₹)	EPS basic (₹)	EPS Diluted (₹)	RONW (%)	P/E Ratio	NAV (₹)
Powerica Limited	5	15.26	15.26	15.37 %	24.45	99.76
Listed Peers
Cummins India Limited	2	72.15	72.15	26.45%	64.13	272.78
Kirloskar Oil Engines Limited	2	33.71	33.60	15.85%	43.24	212.60
NTPC Green Energy Limited	10	0.67	0.67	2.58%	129.40	21.88
Acme Solar Holdings Limited	2	4.55	4.53	5.59%	50.74	74.54
Adani Green Energy Limited	10	8.37	8.37	11.90%	101.53	76.62

Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion

Q-Line Biotech IPO FAQs

1. What is Q-Line Biotech IPO? ⌄

Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.

2. When Q-Line Biotech IPO will open for subscription? ⌄

The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.

3. What is Q-Line Biotech IPO Investors Portion? ⌄

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

4. How to Apply the Q-Line Biotech IPO? ⌄

You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

5. What is Q-Line Biotech IPO Issue Size? ⌄

Q-Line Biotech IPO issue size is ₹214 crores.

6. What is Q-Line Biotech IPO Price Band? ⌄

Q-Line Biotech IPO Price Band is ₹326 to ₹343.

7. What is Q-Line Biotech IPO Lot Size? ⌄

The minimum bid is 800 Shares with ₹2,74,400 amount.

8. What is the Q-Line Biotech IPO Allotment Date? ⌄

Q-Line Biotech IPO allotment date is May 26,2026.

9. What is the Q-Line Biotech IPO Listing Date? ⌄

Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Emmforce Autotech IPO Date, Review, Price, Allotment Details

By IPOWatch Team
April 23, 2024

Emmforce Autotech IPO Details: Emmforce Autotech IPO date is fixed, The IPO will open on April 23 and will close on April 25. Emmforce Autotech is a NSE SME IPO to raise ₹53.90 crores via IPO. The Emmforce Autotech IPO price band is fixed at ₹93 to ₹98 with a market lot of 1200 shares.

Emmforce Autotech is engaged in the business of manufacturing niche automotive drivetrain parts like Differential Housings, Differential Lockers, Differential Covers,4WD Locking Hubs, Spindles, Axles & Shafts, Gear Shifters, Yokes, Differential Spools, Differential Tools and various differential forged/cast parts primarily for 4-wheel Drive and performance racing vehicles. The company has been engaged in exports ever since its inception. They have established itself as a manufacturer of Drivetrain Parts in India and is a stop shop for quality cost cost-effective drivetrain parts and provides out-of-the-box solutions to its customers through designing and developing complex/special parts.

A huge inventory of tooling for forging and machining, jigs and fixtures for machining, and extra focus on engineering gives Emmforce an edge over the competition to develop new parts in a much faster time than the competition. Their company helps to accelerate performance and improve profitability through faster product development, shorter lead time, on-time delivery, comprehensive product range, and competitive pricing.

They offer fully integrated engineering solutions from conceptualization, development, and validation to implementation and manufacturing of their products. The conceptualization stage involves acquiring market intelligence, assessing customer requirements, and formulating customized strategies for individual customers. The development phase includes product designing, material procurement, and processing. This is followed by the validation phase, which involves prototyping, testing, and feasibility analysis. Their in-house manufacturing and implementation competencies include forging, machining, fabrications, heat treatment, surface finish, logistics, quality and testing, design, and validation.

Objects of the Issue:

Investment in a Subsidiary Company i.e. Emmforce Mobility Solutions Private Limited (EMSPL) in the form of equity or debt for meeting the requirement of working capital and margin money for term loan of the Subsidiary Company.
To Meet the Working Capital Requirements of the company.
General Corporate Purpose.

Emmforce Autotech IPO Review

May Apply

Emmforce Autotech IPO Date & Price Band Details

IPO Open:	April 23, 2024
IPO Close:	April 25, 2024
IPO Size:	Approx ₹53.90 Crores, 5,499,600 Equity Shares
Face Value:	₹10 Per Equity Share
IPO Price Band:	₹93 to ₹98 Per Equity Share
IPO Listing on:	NSE SME
Retail Quota:	35% of the net offer
QIB Quota:	50% of the net offer
NII Quota:	15% of the net offer
DRHP Draft Prospectus:	Click Here
RHP Draft Prospectus:	Click Here
Anchor Investors in IPO:	Click Here

Emmforce Autotech IPO Market Lot

The Emmforce Autotech IPO minimum market lot is 1200 shares with a ₹117,600 application amount.

Application	Lot Size	Shares	Amount
Retail Minimum	1	1200	₹117,600
Retail Maximum	1	1200	₹117,600
S-HNI Minimum	2	2400	₹235,200

Emmforce Autotech IPO Dates

The Emmforce Autotech IPO date is April 23 and the IPO close date is April 25. The IPO allotment date is April 26 and the IPO might list on April 30.

IPO Open Date:	April 23, 2024
IPO Close Date:	April 25, 2024
Basis of Allotment:	April 26, 2024
Refunds:	April 29, 2024
Credit to Demat Account:	April 29, 2024
IPO Listing Date:	April 30, 2024

You can check IPO subscription status and IPO allotment status on their respective pages.

Emmforce Autotech IPO Form

How to apply Emmforce Autotech IPO? You can apply Emmforce Autotech IPO via ASBA available in your bank account. Just go to the online bank login and apply via your bank account by selecting the Emmforce Autotech IPO in the Invest section. The other option you can apply Emmforce Autotech IPO via IPO forms download via the NSE website. Check out the Emmforce Autotech forms – click NSE IPO Forms download, fill and submit in your bank or with your broker.

Emmforce Autotech Company Financial Report

₹ in Crores
Year	Revenue	Expense	PAT
2021	₹51.85	₹43.60	₹5.09
2022	₹71.38	₹60.17	₹7.33
2023	₹48.75	₹41.98	₹4.39
October 2023	₹5.19	₹4.59	₹0.44

Emmforce Autotech IPO Valuation – FY2023

Check Emmforce Autotech IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.

Earning Per Share (EPS):	₹2.93 per Equity Share
Price/Earning P/E Ratio:	[.]
Return on Net Worth (RoNW):	18.71%
Net Asset Value (NAV):	₹15.63 per Equity Share

Peer Group

Divgi Torqtransfer Systems Ltd

Company Promoters

Mr. Ashok Mehta
Mrs. Neetu Mehta
Mr. Azeez Mehta

Emmforce Autotech IPO Registrar

Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email: emmforce.ipo@linkintime.co.in
Website: https://linkintime.co.in/initial_offer/public-issues.html

Emmforce Autotech IPO Allotment Status

Check Emmforce Autotech IPO allotment status on Link Intime website URL. Click Here

Emmforce Autotech IPO Lead Managers aka Merchant Bankers

Beeline Capital Advisors Pvt Ltd

Company Address

Emmforce Autotech Limited
Plot No. 287, Industrial Area,
Phase II Industrial Estate,
Panchkula – 134113
Phone: +91- 9876009999
Email: info@emmforce.com
Website: http://www.emmforce.com/

Emmforce Autotech IPO FAQs

What is Emmforce Autotech IPO?

Emmforce Autotech IPO is an NSE SME IPO. They are going to raise ₹53.90 Crores via IPO. The issue is priced at ₹93 to ₹98 per equity share. The IPO is to be listed on NSE.

When Emmforce Autotech IPO will open?

The IPO is to open on April 23, 2024 for QIB, NII, and Retail Investors.

What is Emmforce Autotech IPO Investors Portion?

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

How to Apply the Emmforce Autotech IPO?

You can apply Emmforce Autotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

How to Apply the Emmforce Autotech IPO through Zerodha?

Log in to Console in Zerodha Website or in Application. Go to Portfolio and Click on IPO. You will see the IPO Name “Naman In-Store (India)”. Click on Bid Button. Enter your UPI ID, Quantity, and Price. Submit IPO Application Form. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Zerodha.

How to Apply the Emmforce Autotech IPO through Upstox?

Log in to Upstox Application with your credentials. Select the IPO. You will see the IPO Name “Naman In-Store (India)”. Click on Bid Button. Confirm your application. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Upstox.

How to Apply the Emmforce Autotech IPO through Paytm Money?

Log in to Paytm Money Application with your credentials. Select the IPO. You will see the IPO Name “Naman In-Store (India)”. Click on Bid Button. Confirm your application. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Paytm Money.

What is Emmforce Autotech IPO Size?

Emmforce Autotech IPO size is ₹53.90 crores.

What is Emmforce Autotech IPO Price Band?

Emmforce Autotech IPO Price Band is ₹93 to ₹98 per equity share.

What is Emmforce Autotech IPO Minimum and Maximum Lot Size?

The IPO bid is 1200 shares with ₹117,600.

What is Emmforce Autotech IPO Allotment Date?

Emmforce Autotech IPO allotment date is April 26, 2024.

What is Emmforce Autotech IPO Listing Date?

Emmforce Autotech IPO listing date is April 30, 2024. The IPO to list on NSE SME.

Note: The Emmforce Autotech IPO details are announced officially. The IPO grey market premium (Emmforce Autotech IPO Premium) is updated on the respective page. You can check our IPO grey market page for daily updates.